Harvard Bioscience, Inc. (NASDAQ:HBIO) CFO Robert E. Gagnon sold 97,087 shares of the company’s stock in a transaction on Wednesday, March 7th. The shares were sold at an average price of $4.62, for a total value of $448,541.94. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) opened at $4.75 on Wednesday. Harvard Bioscience, Inc. has a 1-year low of $2.25 and a 1-year high of $5.20. The firm has a market capitalization of $160.45, a PE ratio of -240.00 and a beta of 1.32. The company has a quick ratio of 1.87, a current ratio of 3.40 and a debt-to-equity ratio of 0.13.

How to Become a New Pot Stock Millionaire

Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings results on Thursday, March 1st. The medical instruments supplier reported $0.05 earnings per share for the quarter, meeting the consensus estimate of $0.05. Harvard Bioscience had a positive return on equity of 2.38% and a negative net margin of 0.85%. The firm had revenue of $27.46 million for the quarter, compared to analysts’ expectations of $26.60 million. equities research analysts forecast that Harvard Bioscience, Inc. will post 0.11 earnings per share for the current year.

HBIO has been the topic of a number of recent research reports. Zacks Investment Research raised Harvard Bioscience from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a report on Thursday, March 8th. Janney Montgomery Scott raised their price target on Harvard Bioscience from $5.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, January 24th. Finally, Benchmark raised their price target on Harvard Bioscience from $6.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, January 23rd. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $7.75.

Several institutional investors have recently made changes to their positions in HBIO. Wells Fargo & Company MN increased its position in shares of Harvard Bioscience by 2,013.7% during the 4th quarter. Wells Fargo & Company MN now owns 32,446 shares of the medical instruments supplier’s stock valued at $107,000 after purchasing an additional 30,911 shares during the last quarter. Northern Trust Corp increased its position in shares of Harvard Bioscience by 5.2% during the 2nd quarter. Northern Trust Corp now owns 86,205 shares of the medical instruments supplier’s stock valued at $220,000 after purchasing an additional 4,260 shares during the last quarter. New York State Common Retirement Fund bought a new position in shares of Harvard Bioscience during the 3rd quarter valued at about $321,000. AXA increased its position in shares of Harvard Bioscience by 16.7% during the 4th quarter. AXA now owns 167,500 shares of the medical instruments supplier’s stock valued at $553,000 after purchasing an additional 24,000 shares during the last quarter. Finally, Algert Global LLC increased its position in shares of Harvard Bioscience by 31.0% during the 3rd quarter. Algert Global LLC now owns 149,094 shares of the medical instruments supplier’s stock valued at $559,000 after purchasing an additional 35,276 shares during the last quarter. Hedge funds and other institutional investors own 63.54% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Harvard Bioscience, Inc. (HBIO) CFO Robert E. Gagnon Sells 97,087 Shares” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.dailypolitical.com/2018/03/14/harvard-bioscience-inc-hbio-cfo-robert-e-gagnon-sells-97087-shares.html.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Insider Buying and Selling by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.